All News

Pharmaceutical Executive

Health IT is going through an era of both expansion and convergence, in which the universe of available information is growing exponentially.

Pharmaceutical Executive

We spend a lot of time focusing on what our advertising says to physicians, what our reps say to physicians, and what our websites and various other channels communicate to patients.

Pharmaceutical Executive

In response to the recent shooting at Fort Hood that killed four (including the killer’s suicide) and wounded 16, the mental health watchdog Citizens Commission on Human Rights (CCHR) views this and other recent incidents as a wake-up call to the dangers of antidepressants.

PAAS_ArticleRail-SpecialSection_250_1.gif

Pharmaceutical Executive

Patient adherence to medicine is the eternal puzzle for big Pharma: what combinations of financial incentives, personalized interventions, and just good information work best to push down that stubborn 50 per cent abandonment threshold after six months of treatment?

PHouston_blog_size.jpg

Pharmaceutical Executive

A few weeks back I wrote on this blog about the need for CEOs to get social. I’m realistic, I know that the majority of CEOs still don’t engage directly in social media. Mostly it’s “the team” that does it, the marketing team, or the social media team, or the whole team. Great. Have you told them what rules they’re playing by?

Pharmaceutical Executive

Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault in Dublin, Ireland, last week, at a conference organized under the auspices of the Irish Presidency of the European Union and featuring a galaxy of Irish and European stars from the worlds of politics, regulation, research, industry and patients.

Pharmaceutical Executive

Either the doctor’s best friend or nightmare, the e-patient movement (the ‘e’ could stand for engaged or empowered) is here to stay and growing, writes Marylyn Donahue.

Pharmaceutical Executive

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) - at the time the first TB drug approval in 40 years - “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.